Acidron IV Infusion 4 mg/5 ml

Acidron IV Infusion, manufactured by ACI Limited, contains Zoledronic Acid (4 mg/5 ml) for managing bone-related complications. This IV Infusion medication is priced at ৳5,000.00 per unit. It primarily treats hypercalcemia of malignancy, bone metastases, and osteoporosis while inhibiting excessive bone resorption.

The drug belongs to bisphosphonate preparations, targeting osteoclast activity to regulate calcium levels. Clinical studies confirm its efficacy in reducing tumor-induced hypercalcemia within 4-7 days. Patients receive 4 mg via slow IV infusion every 3-4 weeks, supplemented with calcium and vitamin D for optimal bone health.

Key indications include:

• Malignancy-related hypercalcemia
• Osteolytic lesions in multiple myeloma
• Postmenopausal/corticosteroid-induced osteoporosis
• Paget’s disease management

Store below 30°C, protected from moisture/light. Avoid use in pregnancy, breastfeeding, and pediatric patients.

Common side effects encompass flu-like symptoms, hypocalcemia, and gastrointestinal issues. Drug interactions with aminoglycosides or diuretics may worsen calcium imbalance. Always consult physicians before combining with nephrotoxic agents.

For detailed insights on Zoledronic Acid, visit Medexly. Acidron IV Infusion 4 mg/5 ml offers targeted therapy for complex bone disorders, backed by ACI Limited’s quality assurance.

4 mg single-dose IV infusion over 15 mins for hypercalcemia. Renal dose adjustment required for CrCl <60 mL/min. Administer every 3-4 weeks for metastatic bone lesions. Daily 500 mg calcium + 400 IU vitamin D supplementation recommended.

The post-dose side-effects are headache, nausea, anorexia, fatigue, osteonecrosis of jaw, anemia, bone pain, constipation, fever, vomiting, flu-like syndrome, hypocalcemia, myalgia, arthralgia and hypophosphataemia.

Zoledronic acid is Pregnancy Category D. Contraindicated in breastfeeding. Women of childbearing potential must use contraception.

Pre-hydrate with 500 mL 0.9% saline pre-infusion. Monitor serum electrolytes and renal function. Dental exam recommended pre-treatment in cancer patients.

Renal dose adjustment mandatory (CrCl 30-60 mL/min: 3-3.5 mg). Not studied in hepatic impairment. Geriatric patients require creatinine clearance assessment.

Clinical experience with acute over dosage is limited. Over dosage may cause hypocalcemia, hypophosphatemia, and hypomagnesemia. In such case, reduction in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate and magnesium sulfate respectively.